<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-23T14:57:07Z</responseDate><request verb="GetRecord" identifier="oai:gumushane-rdlopen.rawdatalibrary.net:gumushane/10428" metadataPrefix="oai_dc">https://gumushane-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:gumushane-rdlopen.rawdatalibrary.net:gumushane/10428</identifier><datestamp>2026-10-22T11:07:34Z</datestamp><setSpec>openaire</setSpec><setSpec>com_gumushane_10000</setSpec><setSpec>col_gumushane_10001</setSpec><setSpec>com_gumushane_10007</setSpec><setSpec>col_gumushane_10171</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Carbonic anhydrase I and II autoantibodies in Behcet's disease</dc:title><dc:creator>Mentese, A.</dc:creator><dc:creator>Alver, A.</dc:creator><dc:creator>Demir, S.</dc:creator><dc:creator>Sumer, A.</dc:creator><dc:creator>Yaman S, Ozer</dc:creator><dc:creator>Karkucak, M.</dc:creator><dc:creator>Capkin A, Aydin</dc:creator><dc:creator>Us, Altay D.</dc:creator><dc:creator>Turan, I</dc:creator><dc:subject>Autoantibody</dc:subject><dc:subject>Behcet's disease</dc:subject><dc:subject>Carbonic anhydrase</dc:subject><dc:description>Background: Behcet's disease ( BD) is a vasculitis, seen more frequently around the Mediterranean and the Far East, and evinces with oral and genital ulcerations, skin lesions and uveitis. Carbonic anhydrase ( CA) is a metalloenzyme which is widely distributed in the living world, and it is essential for the regulation of acid-base balance. Anti-CA antibodies have been reported in many disorders, such as systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, endometriosis, idiopathic chronic pancreatitis, type 1 diabetes and Graves' disease. The goal of this study was to investigate CA I and II autoantibodies in BD. Methods: 35 patients with BD and 29 healthy controls were included in the study and CA I and II autoantibody levels were investigated by ELISA. Results: The CA I and II autoantibody levels of BD group were significantly higher than the healthy group (p= 0.013, p= 0.0001, respectively). A cut-off value of 0.250 absorbance unit (ABSU) for anti-CA I was associated with 34% sensitivity and 100% specificity and a cut-off value of 0.171 ABSU for anti-CA II was associated with 54% sensitivity and 100% specificity for predicting BD. Conclusion: The CA I and II autoantibody levels in pa-tients with BD were found higher compared to control group and the results suggest that CA I and II autoantibodies may be involved in the pathogenesis of BD</dc:description><dc:publisher>PUBLISAUDE-EDICOES MEDICAS LDA</dc:publisher><dc:date>2017-01</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/gumushane/10428</dc:identifier><dc:identifier>0303-464X</dc:identifier><dc:language>en</dc:language><dc:relation>ACTA REUMATOLOGICA PORTUGUESA</dc:relation><dc:rights>info:eu-repo/semantics/closedAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://gumushane-rdlopen.rawdatalibrary.net/tr/items/gumushane/10428</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>